Rheumatoid Arthritis (RA) is a long-lasting disease that causes your joints to hurt, swell, and feel stiff. This research study is looking at two medicines, upadacitinib and adalimumab, to see which works better for RA. Upadacitinib is a pill taken once a day, and adalimumab is a shot given every other week. The study is "double-blinded," meaning neither the participants nor the doctors will know which medicine is being given, to ensure fair results.

Participants will take their assigned medicine for two periods and will be monitored for side effects and improvements in their RA symptoms. The study will involve about 480 people from around the world. You'll need to visit the hospital or clinic regularly for check-ups and to answer questions about how you feel.

• The study has a higher treatment burden compared to normal care.
• Participants will visit a clinic or hospital regularly for check-ups.
• Participants will take either a daily pill or a bi-weekly shot.

This study could help find a better treatment for RA, but you need to be comfortable with the extra visits and monitoring. Always talk to your doctor about any concerns or questions before joining a study.